allergic rhinitis
Conditions
Interventions
Experimental group:hyposensitization
placebo group:antianaphylaxis
Sponsors
Beijing Children's Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 13 Years
Inclusion criteria
Inclusion criteria: 1. Aged 4~17 years old male or female; 2. History with at least 2 years of seasonal (summer and authum) allergic rhinitis, with/without allergic conjunctivitis or asthma; 3. At least level 2 of Artemisia-specific immunoglobulin E (determined by ImmunoCAP), and higher than the level of Artemisiifolia-specific immunoglobulin E; 4. Physical examination qualified; 5. All subjects and their guardians should understand the study well, and written informed consent should be obtained from all guardians before the study.
Exclusion criteria
Exclusion criteria: 1. Patients with drug allergy; 2. Patients with present or a history of heart, liver, kidney, endocrine, digestive tract, immune system and serious or chronic respiratory system diseases; patients prone to mucosal damage such as oral ulcers; and patients with asthma attack, chronic rhinitis or nasosinusitis outside of pollen season; 3. Pateints with severe or uncontrolled asthma or chronic obstructive pulmonary disease (COPD) and pulmonary function index FEV1 less than 80% of estimated value in the screening; 4. Pateints with severe contagions during the screening; 5. Pateints who had participated any clinical study in 3 months before the screening; 6. Patients who were receiving or had received any immunotherapy of pollen allergy in 3 years before the screening; 7. Patients who were receiving treatment of beta-antagoists or angiotensin converting enzyme (ACE) antagoists; 8. Pateints with a history of mental diseases; 9. Pateints who were planning to receive any surgery during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse effects;physical examination;laboratory examination; | — |
Contacts
Public ContactTang Lixing
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed